PDE10A and Huntington disease: Although a clinical trial of PDE10A inhibitors in symptomatic HD patients has reported a lack of efficacy [80], the findings of the present study suggest that the timing of intervention may have been too late, occurring after substantial neurodegenerative changes had already taken place.